ResMed Inc. vs Invesco S&P 500 Momentum ETF — how do they compare? ResMed Inc. trades at $197.45 (market cap $28.81B), while Invesco S&P 500 Momentum ETF trades at $150.08. The key difference: ResMed Inc. pays a 1.21% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | SPMO | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $293.73 | $161.66 |
52-Week Low | $182.82 | $107.84 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Trailing returns across standard periods
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →